



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SETTE *et al.*

Appl. No.: 09/894,018

Filed: June 27, 2001

For: **Method and System for
Optimizing Minigenes and
Peptides Encoded Thereby**

Confirmation No.: 7107

Art Unit: 1631

Examiner: Ardin H. Marschel

Atty. Docket: 2060.0320003/EKS/PAC

First Supplemental Information Disclosure Statement

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450
Sir:

Mail Stop Amendment

Listed on accompanying Forms PTO/SB/08a and PTO/SB/08b are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Copies of all U.S. Patents and U.S. Patent Application Publications, cited on Form PTO/SB/08a as documents **US1-US15**, are not provided in accordance with 37 C.F.R. § 1.98(a)(2).

Copies of documents **NPL69-NPL72** cited on Form PTO/SB/08b are not provided in accordance with the U.S. Patent and Trademark Office OG notice of October 19, 2004, which states: "the requirement in 37 C.F.R. § 1.98(a)(2)(iii) for a legible copy of the specification, including the claims, and drawings of each cited pending U.S. patent application (or portion of the application which caused it to be listed) is *sua sponte* waived where the cited pending application is stored in the USPTO's IFW system."

The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to this application now or upon issuance of the present application as a patent. The

Examiner is respectfully requested to consider the cited application and the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached Forms PTO/SB/08a and PTO/SB/08b based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. § 1.114. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed Forms PTO/SB/08a and PTO/SB/08b, and indicate in the official file wrapper of this patent application that the documents have been considered. The U.S. Patent and Trademark Office is

SETTE *et al.*
Appl. No. 09/894,018

hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit
Account No. 19-0036.


Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

A handwritten signature in black ink, appearing to read "Eric K. Steffe", with a stylized flourish at the end.

Eric K. Steffe
Attorney for Applicants
Registration No. 36,688

Date: 9/9/05
1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	09/894,018
				Filing Date	June 27, 2001
				First Named Inventor	SETTE
				Art Unit	1631
				Examiner Name	Ardin H. Marschel
				Attorney Docket Number	2060.0320003/EKS/PAC
Sheet	1	of	2		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Pages, Columns, Lines
		Number-Kind Code ² (If Known)			
	US1	5,200,320	04/06/1993	Sette <i>et al.</i>	
	US2	5,503,829	04/02/1996	Ladant <i>et al.</i>	
	US3	5,662,907	09/02/1997	Kubo <i>et al.</i>	
	US4	5,846,827	12/08/1998	Celis <i>et al.</i>	
	US5	6,034,214	03/07/2000	Boon <i>et al.</i>	
	US6	6,413,517	07/02/2002	Sette <i>et al.</i>	
	US7	2002/0098197 A1	07/25/2002	Sette <i>et al.</i>	
	US8	2002/0160019 A1	10/31/2002	Sette <i>et al.</i>	
	US9	2002/0177694 A1	11/28/2002	Sette <i>et al.</i>	
	US10	6,534,482	03/18/2003	Fikes <i>et al.</i>	
	US11	2003/0099634 A1	05/29/2003	Vitiello <i>et al.</i>	
	US12	2003/0152580 A1	08/14/2003	Sette <i>et al.</i>	
	US13	2003/0185822 A1	10/02/2003	Grey <i>et al.</i>	
	US14	2003/0203869 A1	10/30/2003	Fikes <i>et al.</i>	
	US15	2003/0220285 A1	11/27/2003	Fikes <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Pages, Columns, Lines	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵				
	FP1	EP 0 044 710 A1	01/27/1982	Scripps Clinic & Research Foundation		
	FP2	EP 0 226 513 A1	06/24/1987	Institut Pasteur		Abs
	FP3	WO 92/02543 A1	02/20/1992	Cytel Corp. <i>et al.</i>		
	FP4	WO 92/12996 A2	08/06/1992	Immune Response Corp.		
	FP5	WO 92/21033 A1	11/26/1992	Max-Planck-Gesellschaft		Abs
	FP6	WO 93/03764 A1	03/04/1993	Cytel Corp.		
	FP7	WO 94/03205 A1	02/17/1994	Cytel Corp.		
	FP8	WO 94/11738 A1	05/26/1994	Max-Planck-Gesellschaft		Abs
	FP9	WO 94/20127 A1	09/15/1994	Cytel Corp.		
	FP10	WO 95/04817 A1	02/16/1995	Cytel Corp.		
	FP11	WO 95/22317 A1	08/24/1995	Cytel Corp.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	09/894,018
				Filing Date	June 27, 2001
				First Named Inventor	SETTE
				Art Unit	1631
				Examiner Name	Ardin H. Marschel
Sheet	2	of	2	Attorney Docket Number	2060.0320003/EKS/PAC

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Pages, Columns, Lines
		Number-Kind Code ² (If Known)			


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Pages, Columns, Lines	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵				
	FP12	WO 96/03140 A1	02/08/1996	Cytel Corp.		
	FP13	WO 97/33602 A1	09/18/1997	Cytel Corp.		
	FP14	WO 97/34621 A1	09/25/1997	Cytel Corp.		
	FP15	WO 98/32456 A1	07/30/1998	Epimmune Inc.		
	FP16	WO 99/45954 A1	09/16/1999	Epimmune Inc.		
	FP17	WO 99/58658 A2	11/18/1999	Epimmune Inc.		
	FP18	WO 99/61916 A1	12/02/1999	Epimmune Inc.		
	FP19	WO 99/65522 A1	12/23/1999	Epimmune Inc.		
	FP20	WO 02/20616	03/14/2002	Epimmune Inc.		
	FP21	WO 02/061435 A2	08/08/2002	Epimmune Inc.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	09/894,018
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	June 27, 2001
				First Named Inventor	SETTE
				Art Unit	1631
				Examiner Name	Ardin H. Marschel
				Attorney Docket Number	2060.0320003
Sheet	1	of	8		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author, title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher	T ²
	NPL1	Aichele, P., <i>et al.</i> , "Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide," <i>J. Exp. Med.</i> 171:1815-1820, Rockefeller University Press (1990)	
	NPL2	Alexander, J., <i>et al.</i> , "Derivation of HLA-A11/K ^b Transgenic Mice. Functional CTL Repertoire and Recognition of Human A11-Restricted CTL Epitopes," <i>J. Immunol.</i> 159:4753-4761, The American Association of Immunologists (November 1997)	
	NPL3	Bertoni, R., <i>et al.</i> , "Human Class I Supertypes and CTL Repertoires Extend to Chimpanzees," <i>J. Immunol.</i> 161:4447-4455, American Association of Immunologists (October 1998)	
	NPL4	Bjorkman, P.J., <i>et al.</i> , "Structure of the human class I histocompatibility antigen, HLA-A2," <i>Nature</i> 329:506-512, Macmillan Publishers, Ltd. (1987)	
	NPL5	Bjorkman, P.J., <i>et al.</i> , "The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens," <i>Nature</i> 329:512-518, Macmillan Publishers, Ltd. (1987)	
	NPL6	Buus, S., <i>et al.</i> , "Autologous Peptides Constitutively Occupy the Antigen Binding Site on Ia," <i>Science</i> 242:1045-1047, American Association for the Advancement of Science (1988)	
	NPL7	Carreno, B.M., <i>et al.</i> , "HLA-B37 and HLA-A2.1 molecules bind largely nonoverlapping sets of peptides," <i>Proc. Natl. Acad. Sci. USA</i> 87:3420-3424, National Academy Press (1990)	
	NPL8	Corr, M., <i>et al.</i> , "Endogenous Peptides of a Soluble Major Histocompatibility Complex Class I Molecule, H-2L ^d _s : Sequence Motif, Quantitative Binding, and Molecular Modeling of the Complex," <i>J. Exp. Med.</i> 176:1681-1692, Rockefeller University Press (December 1992)	
	NPL9	De Bruijn, M.L.H., <i>et al.</i> , "Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses," <i>Eur. J. Immunol.</i> 21:2963-2970, VCH Verlagsgesellschaft mbH (1991)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/894,018
				Filing Date	June 27, 2001
				First Named Inventor	SETTE
				Art Unit	1631
				Examiner Name	Ardin H. Marschel
Sheet	2	of	8	Attorney Docket Number	2060.0320003

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author, title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher	T ²
	NPL10	Deres, K., <i>et al.</i> , "In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine," <i>Nature</i> 342:561-564, Macmillan Publishers, Ltd. (1989)	
	NPL11	DiBrino, M., <i>et al.</i> , "HLA-A1 and HLA-A3 T Cell Epitopes Derived from Influenza Virus Proteins Predicted from Peptide Binding Motifs," <i>J. Immunol.</i> 151:5930-5935, The Association of Immunologists (December 1993)	
	NPL12	DiBrino, M., <i>et al.</i> , "Endogenous peptides bound to HLA-A3 possess a specific combination of anchor residues that permit identification of potential antigenic peptides," <i>Proc. Natl. Acad. Sci. USA</i> 90:1508-1512, National Academy Press (February 1993)	
	NPL13	Ding, Y.-H., <i>et al.</i> , "Two Human T Cell Receptors Bind in a Similar Diagonal Mode to the HLA-A2/Tax Peptide Complex Using Different TCR Amino Acids," <i>Immunity</i> 8:403-11, Cell Press (April 1998)	
	NPL14	Eisenlohr, L.C., <i>et al.</i> , "Flanking Sequences Influence the Presentation of an Endogenously Synthesized Peptide to Cytotoxic T Lymphocytes," <i>J. Exp. Med.</i> 175:481-487, The Rockefeller University Press (February 1992)	
	NPL15	Engelhard, V.H., "Structure of peptides associated with MHC Class I molecules," <i>Curr. Opin. Immunol.</i> 6:13-23, Current Biology, Ltd. (February 1994)	
	NPL16	Falk, K., <i>et al.</i> , "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules," <i>Nature</i> 351:290-296, Macmillan Publishers, Ltd. (1991)	
	NPL17	Falk, K., <i>et al.</i> , "MHC peptide motif register. Peptide motifs of HLA-B35 and -B37 molecules," <i>Immunogenetics</i> 38:161-162, Springer-Verlag (April 1993)	
	NPL18	Falk, K., <i>et al.</i> , "Allele-specific peptide ligand motifs of HLA-C molecules," <i>Proc. Natl. Acad. Sci. USA</i> 90:12005-12009, National Academy Press (December 1993)	
	NPL19	Falk, K., <i>et al.</i> , "Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing, and general rules," <i>Immunogenetics</i> 39:230-242, Springer-Verlag (February 1994)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/894,018
				Filing Date	June 27, 2001
				First Named Inventor	SETTE
				Art Unit	1631
				Examiner Name	Ardin H. Marschel
Sheet	3	of	8	Attorney Docket Number	2060.0320003

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author, title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher	T ²
	NPL20	Falk, K., <i>et al.</i> , "Peptide motifs of HLA-A1, -A11, -A31, and -A33 molecules," <i>Immunogenetics</i> 40:238-241, Springer-Verlag (July 1994)	
	NPL21	Foon, K.A., "Biological Response Modifiers: The New Immunotherapy," <i>Cancer Res.</i> 49:1621-1639, American Association for Cancer Research (1989)	
	NPL22	Geysen, H.M., <i>et al.</i> , "Cognitive Features of Continuous Antigenic Determinants," <i>J. Mol. Recognit.</i> 1:32-41, Heyden & Sons, Ltd. (1988)	
	NPL23	Guo, H.-C., <i>et al.</i> , "Different length peptides bind to HLA-Aw68 similarly at their ends but bulge out in the middle," <i>Nature</i> 360:364-366, Macmillan Publishers, Ltd. (November 1992)	
	NPL24	Henderson, R.A., <i>et al.</i> , "HLA-A2.1-Associated Peptides from a Mutant Cell Line: A Second Pathway of Antigen Presentation," <i>Science</i> 255:1264-1266, American Association for the Advancement of Science (March 1992)	
	NPL25	Hill, A., <i>et al.</i> , "Characterization of two Epstein-Barr virus epitopes restricted by HLA-B7," <i>Eur. J. Immunol.</i> 25:18-24, VCH Verlagsgesellschaft mbH (January 1995)	
	NPL26	Jameson, S.C., and Bevan, M.J., "Dissection of major histocompatibility complex (MHC) and T cell receptor contact residues in a K ^b -restricted ovalbumin peptide and an assessment of the predictive power of MHC-binding motifs," <i>Eur. J. Immunol.</i> 22:2663-2667, VCH Verlagsgesellschaft mbH (October 1992)	
	NPL27	Jardetzky, T.S., <i>et al.</i> , "Identification of self peptides bound to purified HLA-B27," <i>Nature</i> 353:326-329, Macmillan Publishers, Ltd. (1991)	
	NPL28	Kannagi, M., <i>et al.</i> , "Target Epitope in the Tax Protein of Human T-Cell Leukemia Virus Type I Recognized by Class I Major Histocompatibility Complex-Restricted Cells," <i>J. Virol.</i> 66:2928-2933, American Society for Microbiology (May 1992)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/894,018
				Filing Date	June 27, 2001
				First Named Inventor	SETTE
				Art Unit	1631
				Examiner Name	Ardin H. Marschel
Sheet	4	of	8	Attorney Docket Number	2060.0320003

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author, title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher	T ²
	NPL29	Kast, W.M., <i>et al.</i> , "Protection against lethal Sendai virus infection by <i>in vivo</i> priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide," <i>Proc. Natl. Acad. Sci. USA</i> 88:2283-2287, National Academy Press (1991)	
	NPL30	Kast, W.M., <i>et al.</i> , "Strict peptide length is not required for the induction of cytotoxic T lymphocyte-mediated antiviral protection by peptide vaccination," <i>Eur. J. Immunol.</i> 23:1189-1192, VCH Verlagsgesellschaft mbH (May 1993)	
	NPL31	Krieger, J.I., <i>et al.</i> , "Single amino acid changes in DR and antigen define residues critical for peptide-MHC binding and T cell recognition," <i>J. Immunol.</i> 146:2331-2340, American Association of Immunologists (1991)	
	NPL32	Lipford, G.B., <i>et al.</i> , "Primary <i>in Vivo</i> Responses to Ovalbumin. Probing the Predictive Value of the K ^b Binding Motif," <i>J. Immunol.</i> 150:1212-1222, The American Association of Immunologists (February 1993)	
	NPL33	Maryanski, J.L., <i>et al.</i> , "Synthetic peptides as antigens and competitors in recognition by H-2-restricted cytolytic T cells specific for HLA," <i>J. Exp. Med.</i> 167:1391-1405, Rockefeller University Press (1988)	
	NPL34	Maryanski, J.L., <i>et al.</i> , "Competitor Analogs for Defined T Cell Antigens: Peptides Incorporating a Putative Binding Motif and Polyproline or Polyglycine Spacers," <i>Cell</i> 60:63-72, Cell Press (1990)	
	NPL35	Morrison, J., <i>et al.</i> , "Identification of the nonamer peptide from influenza A matrix protein and the role of pockets of HLA-A2 in its recognition by cytotoxic T lymphocytes," <i>Eur. J. Immunol.</i> 22:903-907, VCH Verlagsgesellschaft mbH (April 1992)	
	NPL36	Niedermann, G., <i>et al.</i> , "The proteolytic fragments generated by vertebrate proteasomes: Structural relationships to major histocompatibility complex class I binding peptides," <i>Proc. Natl. Acad. Sci. USA</i> 93:8572-8577, National Academy Press (August 1996)	
	NPL37	Ochoa-Garay, J., <i>et al.</i> , "The ability of peptides to induce cytotoxic T cells <i>in vitro</i> does not strongly correlate with their affinity for the H-2L ^d molecule: implications for vaccine design and immunotherapy," <i>Mol. Immunol.</i> 34:273-281, Elsevier Science, Ltd. (February 1997)	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/894,018
				Filing Date	June 27, 2001
				First Named Inventor	SETTE
				Art Unit	1631
				Examiner Name	Ardin H. Marschel
Sheet	5	of	8	Attorney Docket Number	2060.0320003

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author, title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher	T ²
	NPL38	Pamer, E.G., <i>et al.</i> , "Precise prediction of a dominant class I MHC-restricted epitome of <i>Listeria monocytogenes</i> ," <i>Nature</i> 353:852-855, Macmillan Publishers, Ltd. (1991)	
	NPL39	Parham, P., <i>et al.</i> , "The Origins of HLA-A,B,C Polymorphism," <i>Immunol. Rev.</i> 143:141-180, Munksgaard (February 1995)	
	NPL40	Parker, K.C., <i>et al.</i> , "Peptide Binding to HLA-A2 and HLA-B27 Isolated from <i>Escherichia coli</i> ," <i>J. Biol. Chem.</i> 267:5451-5459, American Society for Biochemistry and Molecular Biology, Inc. (March 1992)	
	NPL41	Parker, K.C., <i>et al.</i> , "Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2," <i>J. Immunol.</i> 149:3580-3587, American Association of Immunologists (December 1992)	
	NPL42	Rammensee, H.-G., <i>et al.</i> , "Peptides Naturally Presented by MHC Class I Molecules," <i>Annu. Rev. Immunol.</i> 11:213-244, Annual Reviews, Inc. (January 1993)	
	NPL43	Reddehase, M.J., <i>et al.</i> , "A pentapeptide as minimal antigenic determinant for MHC class I-restricted T lymphocytes," <i>Nature</i> 337:651-653, Macmillan Publishers, Ltd. (1989)	
	NPL44	Romero, P., <i>et al.</i> , "H-2K ^d -restricted Antigenic Peptides Share a Simple Binding Motif," <i>J. Exp. Med.</i> 174:603-612, Rockefeller University Press (1991)	
	NPL45	Rothbard, J.B., "Major histocompatibility complex-peptide interactions," <i>Curr. Opin. Immunol.</i> 2:99-105, Current Biology, Ltd. (1989)	
	NPL46	Rötzschke, O., <i>et al.</i> , "Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells," <i>Nature</i> 348:252-254, Macmillan Publishers, Ltd. (1990)	
	NPL47	Rötzschke, O., <i>et al.</i> , "Characterization of Naturally Occurring Minor Histocompatibility Peptides Including H-4 and H-Y," <i>Science</i> 249:283-287, American Association for the Advancement of Science (1990)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/894,018
				Filing Date	June 27, 2001
				First Named Inventor	SETTE
				Art Unit	1631
				Examiner Name	Ardin H. Marschel
Sheet	6	of	8	Attorney Docket Number	2060.0320003

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author, title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher	T ²
	NPL48	Röttschke, O., and Falk, K., "Naturally-occurring peptide antigens derived from the MHC class-I-restricted processing pathway," <i>Immunol. Today</i> 12:447-455, Elsevier Science Publishers, Ltd. (1991)	
	NPL49	Röttschke, O., <i>et al.</i> , "Peptide motifs of closely related HLA class I molecules encompass substantial differences," <i>Eur. J. Immunol.</i> 22:2453-2456, VCH Verlagsgesellschaft mbH (September 1992)	
	NPL50	Röttschke, O., and Falk, K., "Origin, structure and motifs of naturally processed MHC class II ligands," <i>Curr. Opin. Immunol.</i> 6:45-51, Current Biology, Ltd. (February 1994)	
	NPL51	Rudinger, J., "Characteristics of the amino acids as components of a peptide hormone sequence," in <i>Peptide Hormones</i> , Parsons, J.A., ed., University Park Press, Baltimore, MD, pp.1-7 (1976)	
	NPL52	Ruppert, J., <i>et al.</i> , "Prominent Role of Secondary Anchor Residues in Peptide Binding to HLA-A2.1 Molecules," <i>Cell</i> 74:929-937, Cell Press (September 1993)	
	NPL53	Schulz, M., <i>et al.</i> , "Major histocompatibility complex binding and T cell recognition of a viral nonapeptide containing a minimal tetrapeptide," <i>Eur. J. Immunol.</i> 21:1181-1185, VCH Verlagsgesellschaft mbH (1991)	
	NPL54	Sette, A., <i>et al.</i> , "Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis," <i>Proc. Natl. Acad. Sci. USA</i> 86:3296-3300, National Academy Press (1989)	
	NPL55	Sette, A., <i>et al.</i> , "Random association between the peptide repertoire of A2.1 class I and several different DR class II molecules," <i>J. Immunol.</i> 147:3893-3900, The American Association of Immunologists (1991)	
	NPL56	Sette, A., <i>et al.</i> , "The Relationship Between Class I Binding Affinity and Immunogenicity of Potential Cytotoxic T Cell Epitopes," <i>J. Immunol.</i> 153:5586-5592, The American Association of Immunologists (December 1994)	
	NPL57	Sherman, L.A., <i>et al.</i> , "Extracellular Processing of Peptide Antigens That Bind Class I Major Histocompatibility Molecules," <i>J. Exp. Med.</i> 175:1221-1226, The Rockefeller University Press (May 1992)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	09/894,018
				Filing Date	June 27, 2001
				First Named Inventor	SETTE
				Art Unit	1631
				Examiner Name	Ardin H. Marschel
Sheet	7	of	8	Attorney Docket Number	2060.0320003

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author, title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher	T ²
	NPL58	Shimojo, N., <i>et al.</i> , "Specificity of peptide binding by the HLA-A2.1 molecule," <i>J. Immunol.</i> 143:2939-2947, The American Association of Immunologists (1989)	
	NPL59	Sidney, J., <i>et al.</i> , "Several HLA Alleles Share Overlapping Peptide Specificities," <i>J. Immunol.</i> 154:247-259, The American Association of Immunologists (January 1995)	
	NPL60	Wentworth, P.A., <i>et al.</i> , "Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice," <i>Eur. J. Immunol.</i> 26:97-101, VCH Verlagsgesellschaft mbH (January 1996)	
	NPL61	Whitton, J.L., <i>et al.</i> , "Molecular Analyses of a Five-Amino-Acid Cytotoxic T-Lymphocyte (CTL) Epitope: an Immunodominant Region Which Induces Nonreciprocal CTL Cross-Reactivity," <i>J. Virol.</i> 63:4303-4310, American Society for Microbiology (1989)	
	NPL62	Yewdell, J.W., and Bennink, J.R., "Cell Biology of Antigen Processing and Presentation to Major Histocompatibility Complex Class I Molecule-Restricted T Lymphocytes," <i>Adv. Immunol.</i> 52:1-123, Academic Press (July 1992)	
	NPL63	York, I.A., and Rock, K.L., "Antigen processing and presentation by the class I major histocompatibility complex," <i>Annu. Rev. Immunol.</i> 14:369-396, Annual Reviews, Inc. (April 1996)	
	NPL64	Zhang, Q-J., <i>et al.</i> , "An HLA-A11-specific motif in nonamer peptides derived from viral and cellular proteins," <i>Proc. Natl. Acad. Sci. USA</i> 90:2217-2221, National Academy Press (March 1993)	
	NPL65	Parker, K.C., <i>et al.</i> , "Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains," <i>J. Immunol.</i> 152:163-175, The American Association of Immunologists (January 1994)	
	NPL66	Dialog File 351, Accession No. 7180926, Derwent WPI English language abstract for EP 0 226 513 (Document AM1)	
	NPL67	Dialog File 351, Accession No. 9263567, Derwent WPI English language abstract for WO 92/21033 (Document AP1)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/894,018
				Filing Date	June 27, 2001
				First Named Inventor	SETTE
				Art Unit	1631
				Examiner Name	Ardin H. Marschel
Sheet	8	of	8	Attorney Docket Number	2060.0320003

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author, title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher	T ²
	NPL68	Dialog File 351, Accession No. 9888606, Derwent WPI English language abstract for WO 94/11738 (Document AN2)	
	NPL69	U.S. Patent Application No. 08/349,177, Grey <i>et al.</i> , filed December 2, 1994 (NOT PUBLISHED)	
	NPL70	U.S. Patent Application No. 09/017,735, Grey <i>et al.</i> , filed February 3, 1998 (NOT PUBLISHED)	
	NPL71	U.S. Patent Application No. 09/189,702, Sette <i>et al.</i> , filed December 10, 1998 (NOT PUBLISHED)	
	NPL72	U.S. Patent Application No. 10/030,014, Sette <i>et al.</i> , filed July 24, 2002 (NOT PUBLISHED)	


Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SETTE *et al.*

Appl. No.: 09/894,018

Filed: June 27, 2001

For: **Method and System for
Optimizing Minigenes and
Peptides Encoded Thereby**

Confirmation No.: 7107

Art Unit: 1631

Examiner: Ardin H. Marschel

Atty. Docket: 2060.0320003/EKS/PAC

Second Supplemental Information Disclosure Statement

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450
Sir:

Mail Stop Amendment

Listed on accompanying Forms PTO/SB/08a and PTO/SB/08b are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Copies of all U.S. Patents and U.S. Patent Application Publications, cited on Form PTO/SB/08a as documents **AA100-AJ100**, **AA101-AJ101** and **AA102-AC102**, are not provided in accordance with 37 C.F.R. § 1.98(a)(2).

A Copy of document **NPL149** cited on Form PTO/SB/08b is not provided in accordance with the U.S. Patent and Trademark Office OG notice of October 19, 2004, which states: "the requirement in 37 C.F.R. § 1.98(a)(2)(iii) for a legible copy of the specification, including the claims, and drawings of each cited pending U.S. patent application (or portion of the application which caused it to be listed) is *sua sponte* waived where the cited pending application is stored in the USPTO's IFW system."

The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to this application now or upon issuance of the present application as a patent. The

Examiner is respectfully requested to consider the cited application and the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached Forms PTO/SB/08a and PTO/SB/08b based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. § 1.114. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed Forms PTO/SB/08a and PTO/SB/08b, and indicate in the official file wrapper of this patent application that the documents have been considered. The U.S. Patent and Trademark Office is

SETTE *et al.*
Appl. No. 09/894,018

hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit
Account No. 19-0036.


Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Eric K. Steffe
Attorney for Applicants
Registration No. 36,688

Date: 9/9/05
1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600



Substitute for form 1449A/Patent Supplemental Information Disclosure Statement by Applicant		Complete If Known	
		Application Number	09/894,018
		Filing Date	June 27, 2001
		First Named Inventor	SETTE
		Art Unit	1631
		Examiner Name	Ardin H. Marschel
		Attorney Docket Number	2060.0320003/EKS/PAC
Sheet	1	of	2

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (If Known)			
	AA100	4,235,877	11/25/1980	Fullerton	
	AB100	4,487,715	12/11/1984	Nitecki <i>et al.</i>	
	AC100	4,599,230	07/08/1986	Milich <i>et al.</i>	
	AD100	4,837,028	06/06/1989	Allen	
	AE100	5,013,548	05/07/1991	Haynes <i>et al.</i>	
	AF100	5,128,319	07/07/1992	Arlinghaus	
	AG100	5,783,567	07/21/1998	Hedley <i>et al.</i>	
	AH100	6,037,135	03/14/2000	Kubo <i>et al.</i>	
	AI100	6,413,935	07/02/2002	Sette <i>et al.</i>	
	AJ100	6,419,931	07/16/2002	Vitiello <i>et al.</i>	
	AA101	6,602,510	08/05/2003	Fikes <i>et al.</i>	
	AB101	2002/0160960	10/31/2002	Sette <i>et al.</i>	
	AC101	2002/0168374	11/14/2002	Kubo <i>et al.</i>	
	AD101	2003/0143672	07/31/2003	Tangri <i>et al.</i>	
	AE101	2003/0216342	11/20/2003	Fikes <i>et al.</i>	
	AF101	2003/0216343	11/20/2003	Fikes <i>et al.</i>	
	AG101	2004/0096445	05/20/2004	Sidney <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Kind Code ⁵ (in known)				
	AL100	EP 0 378 881	06/09/1993	Eniricerche S.p.A.		
	AM100	EP 0 429 816	06/05/1991	F. Hoffmann-La Roche AG		
	AN100	EP 0 433 242	06/19/1991	Fondazione Andrea Cesalpino		
	AO100	WO 93/03764	03/04/1993	Cytel Corporation		
	AP100	WO 94/20127	09/15/1994	Cytel Corporation		
	AQ100	WO 95/07707	03/23/1995	Cytel Corporation		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ⁴ Kind Code ⁵ (in known)				
	AM101	WO 96/22067	07/25/1996	United Biomedical		
	AN101	WO 97/41440	11/06/1997	Rijksuniversiteit te Leiden and Seed Capital Investments		
	AO101	WO 97/34617	09/25/1997	Cytel Corporation		
	AP101	WO 01/00225	01/04/2001	Epimmune Inc.		
Examiner Signature					Date Considered	

440707 1.DOC

Rev. 11-03-03 svb



Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete If Known		
			Application Number	09/894,018	
			Filing Date	June 27, 2001	
			First Named Inventor	SETTE	
			Art Unit	1631	
			Examiner Name	Ardin H. Marschel	
Sheet	1	of	9	Attorney Docket Number	2060.0320003/EKS/PAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL81	Alexander, J., <i>et al.</i> , "Development of High Potency Universal DR-Restricted Helper Epitopes by Modification of High Affinity DR-Blocking Peptides," <i>Immunity</i> 1:751-761, Cell Press (1994)	
	NPL82	Barouch, D., <i>et al.</i> , "HLA-A2 Subtypes Are Functionally Distinct in Peptide Binding and Presentation," <i>J. Exp. Med.</i> 182:1847-1856, Rockefeller University Press (1995)	
	NPL83	Bender, A., <i>et al.</i> , "Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood," <i>J. Immunol. Methods</i> 196:121-135, Elsevier Science (1996)	
	NPL84	Ben-Yedidia, T., and Arnon, R., "Design of peptide and polypeptide vaccines," <i>Curr. Opin. Biotechnol.</i> 8:442-448, Current Biology, Ltd. (1997)	
	NPL85	Carbone, F.R., and Bevan, M.J., "Induction of Ovalbumin-Specific Cytotoxic T Cells by In Vivo Peptide Immunization," <i>J. Exp. Med.</i> 169:603-612, Rockefeller University Press (1989)	
	NPL86	Carbone, F.R., <i>et al.</i> , "Induction of Cytotoxic T Lymphocytes by Primary In Vitro Stimulation with Peptides," <i>J. Exp. Med.</i> 167:1767-1779, Rockefeller University Press (1988)	
	NPL87	Cassell, D., and Forman, J., "Linked Recognition of Helper and Cytotoxic Antigenic Determinants for the Generation of Cytotoxic T Lymphocytes," <i>Ann. N.Y. Acad. Sci.</i> 532:51-60, New York Academy Of Sciences (1991)	
	NPL88	Deres, K., <i>et al.</i> , "In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine," <i>Nature</i> 342:561-564, Nature Publishing Group (1989)	
	NPL89	del Guercio, M-F., <i>et al.</i> , "Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T Helper Epitopes (PADRE) for antibody responses in vivo," <i>Vaccine</i> 15:441-448, Elsevier Science (March 1997)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete If Known			
			Application Number		09/894,018	
			Filing Date		June 27, 2001	
			First Named Inventor		SETTE	
			Art Unit		1631	
			Examiner Name		Ardin H. Marschel	
Sheet	2	of	9	Attorney Docket Number		2060.0320003/EKS/PAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL90	DiBrino, M., et al., "Endogenous Peptides with Distinct Amino Acid Anchor Residue Motifs Bind to HLA-A1 and HLA-B8," J. Immunol. 152:620-631, American Association of Immunologists (1994)	
	NPL91	DiBrino, M., et al., "The HLA-B14 Peptide Binding Site Can Accommodate Peptides with Different Combinations of Anchor Residues," J. Biol. Chem. 269:32426-32434, American Society for Biochemistry and Molecular Biology (1994)	
	NPL92	Donnelly, J.J., et al., "DNA Vaccines," Annu. Rev. Immunol. 15:617-648, Annual Reviews Inc. (April 1997)	
	NPL93	Francis, M.J., et al., "Non-responsiveness to a foot-and-mouth disease virus peptide overcome by addition of foreign helper T-cell determinants," Nature 330:168-170, Nature Publication Group (1987)	
	NPL94	Fynan, E.F., et al., "DNA vaccines: Protective immunizations by parental, mucosal, and gene-gun inoculations," Proc. Natl. Acad. Sci. USA 90:11478-11482, National Academy of Sciences (1993)	
	NPL95	Golvano, J., et al., "Polarity of immunogens: implications for vaccine design," Eur. J. Immunol. 20:2363-2366, VCH Verlagsgesellschaft mbH (1990)	
	NPL96	Gulukota, K., et al., "Two Complementary Methods for Predicting Peptides Binding Major Histocompatibility Complex Molecules," J. Mol. Biol. 267:1258-1267, Academic Press Limited (April 1997)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete If Known			
			Application Number	09/894,018		
			Filing Date	June 27, 2001		
			First Named Inventor	SETTE		
			Art Unit	1631		
			Examiner Name	Ardin H. Marschel		
Sheet	3	of	9	Attorney Docket Number		2060.0320003/EKS/PAC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T ²	
	NPL97	Hammer, J., et al., "Precise Prediction of Major Histocompatibility Complex Class II-Peptide Interaction Based on Peptide Side Chain Scanning," J. Exp. Med. 180:2353-2358, Rockefeller University Press (1994)		
	NPL98	Hill, C.M., et al., "Exploration of Requirements for Peptide Binding to HLA DRB1*0101 and DRB1*0401," J. Immunol. 152:2890-2898, American Association of Immunologists (1994)		
	NPL99	Huczko, E.L., et al., "Characteristics of Endogenous Peptides Eluted from the Class I MHC Molecule HLA-B7 Determined by Mass Spectrometry and Computer Modeling," J. Immunol. 151:2572-2587, American Association of Immunologists (1993)		
	NPL100	Ishioka, G.Y., et al., "Class I MHC-restricted, peptide specific cytotoxic T lymphocytes generated by peptide priming in vivo," in Vaccines90: Modern Approaches to New Vaccines Including Prevention of AIDS, Brown, F., et al., eds., Cold Spring harbor Laboratory Press, Cold Spring Harbor, NY, pp. 7-11 (1990)		
	NPL101	Ishioka, G.Y., et al., "Induction of Class I MHC-Restricted, Peptide-Specific Cytolytic T Lymphocytes by Peptide Priming In Vivo," J. Immunol. 143:1094-1100, American Association of Immunologists (1989)		
	NPL102	Jardetzky, T.S., et al., "Peptide binding to HLA-DR1: a peptide with most residues substituted to alanine retains MHC binding," EMBO J. 9:1797-1803, Oxford University Press (1990)		
	NPL103	Kast, W.M., et al., "Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide," Proc. Natl. Acad. Sci. USA 88:2283-2287, National Academy of Sciences (1991)		
	NPL104	Kondo, A., et al., "Two distinct HLA-A*0101-specific submotifs illustrate alternative peptide binding modes," Immunogenetics 45:249-258, Springer-Verlag (January 1997)		
	NPL105	Kubitscheck, U., et al., "Peptide Binding to Class I Molecules of the Major Histocompatibility Complex on the Surface of Living Target Cells," Scand. J. Immunol. 36:341-348, Blackwell Scientific Publications (1992)		
	NPL106	Kubo, R.T., et al., "Definition of Specific Peptide Motifs for Four Major HLA-A Alleles," J. Immunol. 152:3913-3924, American Association of Immunologists (1994)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete If Known			
			Application Number		09/894,018	
			Filing Date		June 27, 2001	
			First Named Inventor		SETTE	
			Art Unit		1631	
			Examiner Name		Ardin H. Marschel	
Sheet	4	of	9	Attorney Docket Number		2060.0320003/EKS/PAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL107	Kumar, A., et al., "Universal T Helper Cell Determinants Enhance Immunogenicity of a Plasmodium falciparum Merozoite Surface Antigen Peptide," J. Immunol. 148:1499-1505, American Association of Immunologists (1992)	
	NPL108	Lasarte, J.-J., et al., "Induction of Cytotoxic T Lymphocytes in Mice against the Principal Neutralizing Domain of HIV-1 by Immunization with an Engineered T-Cytotoxic-T-Helper Synthetic Helper Peptide Construct," Cell. Immunol. 141:211-218, Academic Press Inc. (1992)	
	NPL109	Madden, D.R., et al., "The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation," Nature 353:321-325, Nature Publishing Group (1991)	
	NPL110	Maier, R., et al., "Peptide motifs of HLA-A3, -A24, and -B7 molecules as determined by pool sequencing," Immunogenetics 40:306-308, Springer-Verlag (1994)	
	NPL111	Martinon, F., et al., "Immunization of Mice with Lipopeptides Bypasses the Prerequisite for Adjuvant," J. Immunol. 149:3416-3422, American Association of Immunologists (1992)	
	NPL112	Niedermann, G., et al., "The specificity of proteasomes: impact on MHC class I processing and presentation of antigens," Immunol. Rev. 172:29-48, Munksgaard (December 1999)	
	NPL113	Nikolić-Zugčić, J., and Carbone, F.R., "Peptide Presentation by Class-I Major Histocompatibility Complex Molecules," Immunol. Res. 10:54-65, S. Karger AG (1991)	
	NPL114	O'Sullivan, D., et al., "Characterization of the Specificity of Peptide Binding to Four DR Haplotypes," J. Immunol. 145:1799-1808, American Association of Immunologists (1990)	
	NPL115	O'Sullivan, D., et al., "On the Interaction of Promiscuous Antigenic Peptides with Different DR Alleles," J. Immunol. 147:2663-2669, American Association of Immunologists (1991)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete If Known			
			Application Number	09/894,018		
			Filing Date	June 27, 2001		
			First Named Inventor	SETTE		
			Art Unit	1631		
			Examiner Name	Ardin H. Marschel		
Sheet	5	of	9	Attorney Docket Number		2060.0320003/EKS/PAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL116	Panina-Bordignon, P., et al., "Universally immunogenic T cell eptiopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells," Eur. J. Immunol. 19:2237-2242, VCH Verlagsgesellschaft mbH (1989)	
	NPL117	Penna, A., et al., "Cytotoxic T Lymphocytes Recognize an HLA-A2-Restricted Epitope Within the Hepatitis B Virus Nucleocapsid Antigen," J. Exp. Med. 174:1565-1570, Rockefeller University Press (1991)	
	NPL118	Pryjma, J., et al., "Induction and Suppression of Immunoglobulin Synthesis in Cultures of Human Lymphocytes: Effects of Pokeweed Mitogen and Staphylococcus Aureus Cowan I," J. Immunol. 124:656-661, Williams & Wilkins Co. (1980)	
	NPL119	Rahemtulla, A., et al., "Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4," Nature 353:180-183, Nature Publishing Group (1991)	
	NPL120	Rammensee, H-G., et al., "SYFPEITHI: database for MHC ligands and peptide motifs," Immunogenetics 50:213-219, Springer-Verlag (November 1999)	
	NPL121	Reitermann, A., et al., "Lipopeptide Derivatives of Bacterial Lipoprotein Constitute Potent Immune Adjuvants Combined with or Covalently Coupled to Antigen or Hapten," Biol. Chem. Hoppe Seyler 370:343-352, Walter De Gruyter (1989)	
	NPL122	Saper, M.A., et al., "Refined Structure of the Human Histocompatibility Antigen HLA-A2 at 2.6 Å Resolution," J. Mol. Biol. 219:277-319, Academic Press Ltd. (1991)	
	NPL123	Schaeffer, E.B., et al., "Relative contribution of 'determinant selection' and 'holes in the T-cell repertoire' to T-cell responses," Proc. Natl. Acad. Sci. USA 86:4649-4653, National Academy of Sciences (1989)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete If Known			
			Application Number	09/894,018		
			Filing Date	June 27, 2001		
			First Named Inventor	SETTE		
			Art Unit	1631		
			Examiner Name	Ardin H. Marschel		
Sheet	6	of	9	Attorney Docket Number		2060.0320003/EKS/PAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL124	Schumacher, T.N.M., et al., "Peptide selection by MHC class I molecules," Nature 350:703-706, Nature Publishing Group (1991)	
	NPL125	Sette, A., and Sidney, J., "HLA supertypes and supermotifs: a functional perspective on HLA polymorphism," Curr. Opin. Immunol. 10:478-482, Current Biology Publications (August 1998)	
	NPL126	Sette, A., et al., "A Novel Approach to the Generation of High Affinity Class II-Binding Peptides," J. Immunol. 145:1809-1813, American Association of Immunologists (1990)	
	NPL127	Sette, A., et al., "Peptide Binding to the Most Frequent HLA-A Class I Alleles Measured by Quantitative Molecular Binding Assays," Mol. Immunol. 31:813-822, Pergamon Press (1994)	
	NPL128	Sidney, J., et al., "Definition of an HLA-A3-Like Supermotif Demonstrates the Overlapping Peptide-Binding Repertoires of Common HLA Molecules," Hum. Immunol. 45:79-93, Elsevier Science Inc. (1996)	
	NPL129	Sidney, J., et al., "Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs," Immunol. Today 17:261-266, Elsevier Science (1996)	
	NPL130	Sidney, J., et al., "The HLA-A*0207 Peptide Binding Repertoire is Limited to a Subset of the A*0201 Repertoire," Hum. Immunol. 58:12-20, Elsevier Science Inc. (November 1997)	
	NPL131	Sinigaglia, F., and Hammer, J., "Defining rules for the peptide-MHC class II interaction," Curr. Opin. Immunol. 6:52-56, Current Biology Ltd. (1994)	
	NPL132	Southwood, S., et al., "Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires," J. Immunol. 160:3363-3373, American Association of Immunologists (April 1998)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete If Known			
			Application Number	09/894,018		
			Filing Date	June 27, 2001		
			First Named Inventor	SETTE		
			Art Unit	1631		
			Examiner Name	Ardin H. Marschel		
Sheet	7	of	9	Attorney Docket Number		2060.0320003/EKS/PAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL133	Sprent, J., and Schaefer, M., "Properties of Purified T Cell Subsets. I. In Vitro Responses to Class I vs. Class II H-2 Alloantigens," <i>J. Exp. Med.</i> 162:2068-2088, Rockefeller University Press (1985)	
	NPL134	Stark, J.M., et al., "Immunogenicity of lipid-conjugated antigens. I. The Influence of Chain Length and Degree of Conjugation on Induction of Antibody in Mice," <i>Immunology</i> 39:345-352, Blackwell Scientific Publications (1980)	
	NPL135	Steinman, R.M., "Dendritic cells and immune-based therapies," <i>Exp. Hematol.</i> 24:859-862, Elsevier Science Inc. (1996)	
	NPL136	Sudo, T., et al., "Differences in MHC Class I Self Peptide Repertoires Among HLA-A2 Subtypes," <i>J. Immunol.</i> 155:4749-4756, American Association of Immunologists (1995)	
	NPL137	Sugawara, S., et al., "A simple method to eliminate the antigenicity of surface class I MHC molecules from the membrane of viable cells by acid treatment at pH 3," <i>J. Immunol. Methods</i> 100:83-90, Elsevier Science (1987)	
	NPL138	Tam, J.P., and Lu, Y-A., "Vaccine engineering: Enhancement of immunogenicity of synthetic peptide vaccines related to hepatitis in chemically defined models consisting of T- and B-cell epitopes," <i>Proc. Natl. Acad. Sci. USA</i> 86:9084-9088, National Academy of Sciences (1989)	
	NPL139	Townsend, A., and Bodmer, H., "Antigen Recognition by Class I-Restricted T Lymphocytes," <i>Ann. Rev. Immunol.</i> 7:601-624, Annual Reviews, Inc. (1989)	
	NPL140	von Boehmer, H., and Haas, W., "Distinct Ir Genes for Helper and Killer Cells in the Cytotoxic Response to H-Y Antigen," <i>J. Exp. Med.</i> 150:1134-1142, Rockefeller University Press (1979)	
	NPL141	Watari, E., et al., "A Synthetic Peptide Induces Long-Term Protection from Lethal Infection with Herpes Simplex Virus 2," <i>J. Exp. Med.</i> 165:459-470, Rockefeller University Press (1987)	
	NPL142	Wentworth, P.A., et al., "In Vitro Induction of Primary, Antigen-Specific CTL from Human Peripheral Blood Mononuclear Cells Stimulated with Synthetic Peptides," <i>Mol. Immunol.</i> 32:603-612, Elsevier Science Ltd. (1995)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete If Known			
			Application Number	09/894,018		
			Filing Date	June 27, 2001		
			First Named Inventor	SETTE		
			Art Unit	1631		
			Examiner Name	Ardin H. Marschel		
Sheet	8	of	9	Attorney Docket Number		2060.0320003/EKS/PAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL143	Widmann, C., et al., "T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides," J. Immunol. Meth. 155:95-99, Elsevier Science Publishers B.V. (1992)	
	NPL144	Wiesmüller, K-H., et al., "Lipopeptide-Helper-T-Cell Epitope-CTL Epitope Conjugate Induces Antibodies Against the CTL Epitope," Innovation Perspective Solid Phase Synthesis Collect. Papers, Int. Symp. 2nd, pp. 499-502 (1991)	
	NPL145	Wiesmüller, K-H., et al., "Novel low-molecular-weight synthetic vaccine against foot-and mouth disease containing a potent B cell and macrophage activator," Vaccine 7:29-33, Butterworth & Co. (1989)	
	NPL146	Zhou, X., et al., "In vivo primary induction of virus-specific CTL by immunization with 9-mer synthetic peptides," J. Immunol. Methods 153:193-200, Elsevier Science Publishers B.V. (1992)	
	NPL147	Zinkernagel, R.M., et al., "The Lymphoreticular System in Triggering Virus Plus Self-Specific Cytotoxic T Cells: Evidence for T Help," J. Exp. Med. 147:897-911, Rockefeller University Press (1978)	
	NPL148	Altuvia, Y. et al., "A Structure-Based Algorithm to Predict Potential Binding Peptides to MHC Molecules with Hydrophobic Binding Pockets," Human Immunol. 58:1-11, Elsevier Science Inc. (1997)	
	NPL149	U.S. Patent Application No. 10/817,970, Grey et al., filed April 6, 2004 (NOT PUBLISHED)	
	NPL150	An, L-L., and Whitton, J.L., "A Multivalent Minigene Vaccine, Containing B-Cell, Cytotoxic T-Lymphocyte, and T _H Epitopes from Several Microbes, Induces Appropriate Responses In Vivo and Confers Protection against More than One Pathogen," J. Virol. 71:2292-2302, American Society for Microbiology (1997)	
	NPL151	Bergmann, C.C., et al., "Flanking Residues Alter Antigenicity and Immunogenicity of Multi-Unit CTL Epitopes," J. Immunol. 157:3242-3249, American Association of Immunologists (1996)	
	NPL152	Hanke, T., et al., "DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice," Vaccine 16:426-435, Elsevier Science (February 1998)	
	NPL153	Hanke, T., et al., "Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice," J. Gen. Virol. 79:83-90, Society for General Microbiology (January 1998)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	09/894,018
				Filing Date	June 27, 2001
				First Named Inventor	SETTE
				Art Unit	1631
				Examiner Name	Ardin H. Marschel
Sheet	9	of	9	Attorney Docket Number	2060.0320003/EKS/PAC

	NPL154	Iwasaki, A., <i>et al.</i> , "Epitope-specific cytotoxic T lymphocyte induction by minigene DNA immunization," <i>Vaccine</i> 17:2081-2088, Elsevier Science (April 1999)	
	NPL155	Jolivet, M., <i>et al.</i> , "Polyvalent synthetic vaccines: relationship between T epitopes and immunogenicity," <i>Vaccine</i> 8:35-40, Butterworth & Co. (1990)	
	NPL156	Kuhröber, A., <i>et al.</i> , "DNA vaccination with plasmids encoding the intracellular (HBcAg) or secreted (HBeAg) form of the core protein of hepatitis B virus primes T cell responses to two overlapping K ^B - and K ^D -restricted epitopes," <i>Int. Immunol.</i> 9:1203-1212, Oxford University Press (1997)	
	NPL157	Oseroff, C., <i>et al.</i> , "Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL epitope responses," <i>Vaccine</i> 16:823-833, Elsevier (April 1998)	
	NPL158	Sobao, Y., <i>et al.</i> , "Identification of hepatitis B virus-specific CTL epitopes presented by HLA-A*2402, the most common HLA class I allele in East Asia," <i>J. Hepatol.</i> 34:922-929, Elsevier (2001)	
	NPL159	Theobald, M., <i>et al.</i> , "The Sequence Alteration Associated with a Mutational Hotspot in p53 Protects Cells From Lysis by Cytotoxic T Lymphocytes Specific for a Flanking Peptide Epitope," <i>J. Exp. Med.</i> 188:1017-1028, Rockefeller University Press (September 1998)	
	NPL160	Thomson, S.A., <i>et al.</i> , "Delivery of Multiple CD8 Cytotoxic T Cell Epitopes by DNA Vaccination," <i>J. Immunol.</i> 160:1717-1723, American Association of Immunologists (February 1998)	
	NPL161	Thomson, S.A., <i>et al.</i> , "Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8 ⁺ cytotoxic T cells: Implications for vaccine design," <i>Proc Natl. Acad. Sci. USA</i> 92:5845-5849, National Academy of Sciences (1995)	
	NPL162	Thomson, S.A., <i>et al.</i> , "Targeting a Polyepitope Protein Incorporating Multiple Class II-Restricted Viral Epitopes to the Secretory/Endocytic Pathway Facilitates Immune Recognition by CD4 ⁺ Cytotoxic T Lymphocytes: a Novel Approach to Vaccine Design," <i>J. Virol.</i> 72:2246-2252, American Society for Microbiology (March 1998)	
	NPL163	Toes, R.E.M., <i>et al.</i> , "Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion," <i>Proc. Natl. Acad. Sci. USA</i> 94:14660-14665, National Academy of Sciences (1997)	
	NPL164	Wang, Y., <i>et al.</i> , "Silencing of Immunodominant Epitopes by Contiguous Sequences in Complex Synthetic Peptides," <i>Cell. Immunol.</i> 143:284-297, Academic Press (1992)	
	NPL165	Whitton, J.L., <i>et al.</i> , "A 'String-of-Beads' Vaccine, Comprising Linked Minigenes, Confers Protection from Lethal-Dose Virus Challenge," <i>J. Virol.</i> 67:348-352, American Society for Microbiology (1993)	
	NPL166	Woodberry, T., <i>et al.</i> , "Immunogenicity of a Human Immunodeficiency Virus (HIV) Polytope Vaccine Containing Multiple HLA A2 HIV CD8 ⁺ Cytotoxic T-Cell Epitopes," <i>J. Virol.</i> 73:5320-5325, American Society for Microbiology (July 1999)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.